CIK 0001357874 · Non-accelerated filer<br>Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- operating
- Phone
- 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-20 | Pire Shari Lisa Director | Option exercise · Restricted Stock Units | −21,000 | 0 | ||
| 2026-05-20 | Germano Geno J Director | Option exercise | +21,000 | 44,883 | ||
| 2026-05-20 | Germano Geno J Director | Option exercise · Restricted Stock Units | −21,000 | 0 | ||
| 2026-02-18 | Amoroso Michael President and CEO | Sale 10b5-1 | −20,559 | $3.84 | $79K | 243,392 |
| 2026-02-18 | Kelly John Alexander Chief Financial Officer | Sale 10b5-1 | −8,149 | $3.84 | $31K | 125,883 |
| 2026-02-18 | Scimeca Dario General Counsel and Secretary | Sale 10b5-1 | −4,925 | $3.84 | $19K | 56,457 |
| 2026-02-18 | SMITH J. JEFFERSON Chief Research Officer | Sale 10b5-1 | −4,925 | $3.84 | $19K | 121,926 |
| 2026-02-17 | Amoroso Michael President and CEO | Option exercise 10b5-1 | +67,797 | 263,951 | ||
| 2026-02-17 | Amoroso Michael President and CEO | Option exercise · Restricted Stock Units 10b5-1 | −67,797 | 135,593 | ||
| 2026-02-17 | Kelly John Alexander Chief Financial Officer | Option exercise 10b5-1 | +27,584 | 134,032 | ||
| 2026-02-17 | Kelly John Alexander Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −27,584 | 55,166 | ||
| 2026-02-17 | Scimeca Dario General Counsel and Secretary | Option exercise 10b5-1 | +16,667 | 61,382 | ||
| 2026-02-17 | Scimeca Dario General Counsel and Secretary | Option exercise · Restricted Stock Units 10b5-1 | −16,667 | 33,333 | ||
| 2026-02-17 | SMITH J. JEFFERSON Chief Research Officer | Option exercise 10b5-1 | +16,667 | 126,851 | ||
| 2026-02-17 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −16,667 | 33,333 | ||
| 2026-01-22 | Amoroso Michael President and CEO | Sale 10b5-1 | −34,799 | $4.17 | $145K | 196,154 |
| 2026-01-21 | Scimeca Dario General Counsel and Secretary | Sale 10b5-1 | −8,854 | $4.03 | $36K | 44,715 |
| 2026-01-21 | Kelly John Alexander Chief Financial Officer | Sale 10b5-1 | −15,213 | $4.03 | $61K | 106,448 |
| 2026-01-21 | SMITH J. JEFFERSON Chief Research Officer | Option exercise 10b5-1 | +16,219 | 120,384 | ||
| 2026-01-21 | SMITH J. JEFFERSON Chief Research Officer | Sale 10b5-1 | −10,200 | $4.03 | $41K | 110,184 |
Page 2 of 11 · 210 trades